{"argument_date":"2026-04-29T00:00:00Z","arguments":[{"argument_date":"2026-04-29T00:00:00Z","heading":"What happened at the argument","official_detail_url":"https://www.supremecourt.gov/oral_arguments/audio/2025/24-889","official_transcript_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","paragraphs":["Hikma asked the Court to reverse the decision below. It argued that statements consistent with skinny-label use cannot count as active inducement. It contended section 271(b) permits selling dual-use products without active inducement. It invoked Twombly and Iqbal on plausibility. It disputed Amarin's claimed new discovery evidence. It also asserted Hatch-Waxman section viii protections.","Amarin, argued by Michael R. Huston, contested the investor-only characterization of the press releases. It cited Grokster, which described advertising as a classic form of inducement.","The United States argued inducement requires active encouragement. It said lack of discouraging disclaimers is irrelevant. It argued the Federal Circuit erred by giving any weight to a skinny label. It described its test as acts or messages showing clear intent to encourage infringement. It invoked Grokster's clear-expression standard. It said describing a product as a generic equivalent is normal.","The justices tested several assumptions. Justice Sotomayor tested whether Hikma needs new rules and whether the complaint satisfies Twombly and Iqbal. Justice Thomas tested whether generics should state SH-only approval and whether quoting brand praise could induce infringement. Justice Jackson tested the statutory sameness requirement for generic labels. Justice Gorsuch tested a website disclaimer indicating fewer than all indications."],"reargument":false,"sequence":1,"sources":[{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 1, lines 1-9","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 1, lines 1-9"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 10, lines 11-19","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 10, lines 11-19"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 11, lines 53-17","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 11, lines 53-17"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 11, lines 9-15","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 11, lines 9-15"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 12, lines 19-23","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 12, lines 19-23"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 12, lines 37-11","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 12, lines 37-11"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 13, lines 21-43","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 13, lines 21-43"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 15, lines 13-19","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 15, lines 13-19"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 16, lines 35-19","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 16, lines 35-19"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 19, lines 29-33","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 19, lines 29-33"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 21, lines 31-49","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 21, lines 31-49"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 24, lines 49-11","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 24, lines 49-11"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 35, lines 41-53","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 35, lines 41-53"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 41, lines 11-19","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 41, lines 11-19"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 41, lines 21-51","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 41, lines 21-51"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 43, lines 21-15","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 43, lines 21-15"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 5, lines 23-9","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 5, lines 23-9"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 60, lines 29-31","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 60, lines 29-31"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 65, lines 11-43","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 65, lines 11-43"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 7, lines 11-17","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 7, lines 11-17"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 7, lines 19-33","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 7, lines 19-33"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 7, lines 35-49","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 7, lines 35-49"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 8, lines 29-53","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 8, lines 29-53"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 9, lines 31-37","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 9, lines 31-37"}]}],"caption":"Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.","case_history":[{"changed_at":"2026-08-28T20:28:59.859900Z","explanation":"An official oral-argument transcript was verified.","status":"argued"},{"changed_at":"2026-08-29T23:55:33.975573Z","explanation":"An official Court opinion was verified.","status":"decided"},{"changed_at":"2026-08-30T01:28:36.205098Z","explanation":"An official Court opinion was verified.","status":"decided"}],"case_status":"decided","dek":"Amarin Pharma sued Hikma Pharmaceuticals, claiming Hikma's public statements encouraged doctors to infringe Amarin's patent on its drug Vascepa. A district court threw out the complaint. The Supreme Court must decide whether those statements can count as actively inducing patent infringement.","dek_sources":[{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 15, lines 13-19","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 15, lines 13-19"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 21, lines 31-49","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 21, lines 31-49"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 5, lines 23-9","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 5, lines 23-9"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 65, lines 11-43","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 65, lines 11-43"}],"dispositions":[],"latest_court_document_date":"2026-04-29T00:00:00Z","maturity":"post_opinion","official_detail_url":"https://www.supremecourt.gov/oral_arguments/audio/2025/24-889","official_disposition_urls":["https://www.supremecourt.gov/opinions/25pdf/24-889_5i36.pdf"],"official_docket_url":"https://www.supremecourt.gov/docket/docketfiles/html/public/24-889.html","primary_docket":"24-889","revisions":[{"correction_note":null,"created_at":"2026-08-29T04:43:28.441900Z","maturity":"official_transcript","revision_number":1},{"correction_note":"Removed internal claim markers from public prose.","created_at":"2026-08-29T11:39:02.661412Z","maturity":"official_transcript","revision_number":2},{"correction_note":"Rewritten to the concise citizen-facing editorial standard.","created_at":"2026-08-29T15:42:01.334253Z","maturity":"official_transcript","revision_number":3},{"correction_note":"Removed an unsupported statement that the Court had not ruled; the available source set did not establish that absence.","created_at":"2026-08-29T23:48:24.651073Z","maturity":"official_transcript","revision_number":4},{"correction_note":"Corrected unsupported no-ruling language and clarified that the article's disposition summary is incomplete.","created_at":"2026-08-30T00:16:28.835214Z","maturity":"official_transcript","revision_number":5},{"correction_note":"Added the holding and disposition from the verified official Court opinion.","created_at":"2026-08-30T01:28:36.227611Z","maturity":"post_opinion","revision_number":6},{"correction_note":"Migrated to the dated official Court activity contract without model use.","created_at":"2026-09-05T03:22:24Z","maturity":"post_opinion","revision_number":7}],"schema_version":"1.1","sections":[{"heading":"What this case is about","paragraphs":["The dispute centers on generic drug makers and patent liability. Amarin sells the brand drug Vascepa. It sued Hikma and other generic makers, claiming their public statements encouraged doctors to infringe Amarin's patent."],"sources":[{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 15, lines 13-19","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 15, lines 13-19"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 21, lines 31-49","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 21, lines 31-49"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 5, lines 23-9","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 5, lines 23-9"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 65, lines 11-43","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 65, lines 11-43"}]},{"heading":"How the case got here","paragraphs":["A district court, Judge Andrews, granted a motion to dismiss. That means the judge threw out Amarin's complaint without a full trial. Both sides acknowledged this outcome during argument. The Supreme Court agreed to review the dispute."],"sources":[{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 1, lines 1-9","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 1, lines 1-9"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 5, lines 23-9","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 5, lines 23-9"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 60, lines 29-31","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 60, lines 29-31"}]},{"heading":"What each side wants","paragraphs":["Hikma and the other the sides that brought the case want the Court to reverse the dismissal. Charles B. Klein argued for them. They say statements consistent with lawful skinny-label use cannot count as active inducement.","The United States, argued by Malcolm L. Stewart, supported Hikma as amicus. It says inducement requires active encouragement, and failing to add discouraging disclaimers is irrelevant. It argues the Federal Circuit erred by giving any weight to a skinny label. It says describing a product as a generic equivalent of Vascepa is normal."],"sources":[{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 15, lines 13-19","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 15, lines 13-19"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 21, lines 31-49","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 21, lines 31-49"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 5, lines 23-9","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 5, lines 23-9"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 65, lines 11-43","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 65, lines 11-43"}]},{"heading":"What each side says","paragraphs":["Hikma argues statements consistent with skinny-label use cannot count as active inducement. It says section 271(b) permits selling dual-use products without active inducement. It also says Hatch-Waxman section viii protects skinny-label generics from an infringing use.","Hikma adds that Amarin's complaint is not plausible under Twombly and Iqbal. Those standards mean a complaint must show a plausible claim, not just guesses. Hikma says obvious alternative explanations defeat plausibility at the pleading stage. It also disputes Amarin's claimed new discovery evidence of inducement intent. It says the accused statements were anodyne and consistent with non-infringing use."],"sources":[{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 15, lines 13-19","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 15, lines 13-19"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 21, lines 31-49","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 21, lines 31-49"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 5, lines 23-9","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 5, lines 23-9"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 65, lines 11-43","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 65, lines 11-43"}]},{"heading":"What the justices asked","paragraphs":["Justice Sotomayor asked whether Hikma needs new rules and whether the complaint satisfies Twombly and Iqbal. Justice Thomas asked whether generics should state approval for the SH indication only. Justice Thomas also asked whether quoting a brand's praise could induce infringing use.","Justice Jackson asked about the statutory sameness requirement for generic labels, minus the patented indication. Justice Gorsuch asked about a website disclaimer indicating fewer than all indications. Justice Kagan asked whether the press releases were investor-oriented rather than marketing to doctors. Justice Kavanaugh referenced amicus Waxman's concern about the Hatch-Waxman compromise."],"sources":[{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 11, lines 53-17","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 11, lines 53-17"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 35, lines 41-53","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 35, lines 41-53"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 41, lines 11-19","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 41, lines 11-19"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 43, lines 21-15","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 43, lines 21-15"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 7, lines 11-17","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 7, lines 11-17"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 7, lines 35-49","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 7, lines 35-49"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 9, lines 31-37","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 9, lines 31-37"}]},{"heading":"Why it matters","paragraphs":["The case tests how far patent inducement liability reaches into generic drug communications. It also tests the pleading standard for these claims. The Hatch-Waxman compromise for skinny-label generics sits in the background. The outcome could shape what generic makers may say publicly."],"sources":[{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 15, lines 13-19","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 15, lines 13-19"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 21, lines 31-49","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 21, lines 31-49"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 5, lines 23-9","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 5, lines 23-9"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 65, lines 11-43","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 65, lines 11-43"}]},{"heading":"What the Court decided","paragraphs":["A drug maker's ordinary marketing statements about its FDA-approved generic product, without more, do not show it took active steps to encourage doctors to infringe a patent. Amarin therefore failed to state a claim that Hikma actively induced patent infringement under Section 271(b).","The Federal Circuit's judgment was reversed, and the case was sent back for further proceedings."],"sources":[{"evidence_type":"Opinion","label":"Official Supreme Court Opinion — file page 2, lines 1-1","official_url":"https://www.supremecourt.gov/opinions/25pdf/24-889_5i36.pdf","page_label":"file page 2, lines 1-1"},{"evidence_type":"Opinion","label":"Official Supreme Court Opinion — file page 3, lines 1-1","official_url":"https://www.supremecourt.gov/opinions/25pdf/24-889_5i36.pdf","page_label":"file page 3, lines 1-1"}]}],"slug":"2025-24-889-hikma-pharmaceuticals-usa-inc-v-amarin-pharma-inc","term":"2025","title":"Can a Generic Drug Maker's Public Statements Count as Patent Infringement?","title_sources":[{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 15, lines 13-19","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 15, lines 13-19"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 21, lines 31-49","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 21, lines 31-49"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 5, lines 23-9","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 5, lines 23-9"},{"evidence_type":"Transcript","label":"Official Supreme Court Transcript — file page 65, lines 11-43","official_url":"https://www.supremecourt.gov/oral_arguments/argument_transcripts/2025/24-889_2024.pdf","page_label":"file page 65, lines 11-43"}],"topics":[],"undated_disposition_date_fallback":"latest_argument_date","updated_at":"2026-09-05T03:22:24Z"}